1216-44-0

Usage

Uses

Used in Pharmaceutical Development:
FLURENOL-METHYL ESTER is used as a chemical intermediate for the synthesis of pharmaceuticals, leveraging its modified properties to improve the efficacy and safety of drug formulations.
Used in Organic Chemistry Research and Development:
FLURENOL-METHYL ESTER is utilized as a key component in the research and development of new organic compounds, contributing to the advancement of organic chemistry and the discovery of novel substances with potential applications.
Used in Solvent Systems:
FLURENOL-METHYL ESTER is employed as a solvent or solubility enhancer in various chemical processes, taking advantage of its modified solubility properties to facilitate reactions and improve the efficiency of chemical synthesis.
It is crucial to handle FLURENOL-METHYL ESTER with care and adhere to proper safety protocols to mitigate potential hazards associated with its chemical properties.

InChI:InChI=1/C15H12O3/c1-18-14(16)15(17)12-8-4-2-6-10(12)11-7-3-5-9-13(11)15/h2-9,17H,1H3

Upstream product

• 486-25-9 9-fluorenone 
• 84-11-7 9,10-phenanthrenequinone 
• 467-69-6 9-hydroxy-9-fluorene carboxylic acid 
• 139022-32-5 diethyl 9H-fluorene-9,9-dicarboxylate 
• 138723-90-7 2,5-dihydro-2,2-dimethoxy-5,5-dimethyl-1,3,4-oxadiazole 
• 3002-30-0 methyl 9H-fluorene-9-carboxylate 
• 67-56-1 methanol 

Downstream Products

• 876498-21-4 9-(α-hydroxy-4,4'-dimethyl-benzhydryl)-fluoren-9-ol 
• 131807-68-6 3'-(Phenylamino)-2'-thioxo-spiro(9H-fluorene-9,5'-oxazolidin)-4'-one 
• 575433-63-5 tropenol 9-hydroxy-fluorene-9-carboxylate 
• 14718-07-1 10,10-diphenyl-10H-phenanthren-9-one 
• 109399-94-2 9-hydroxy-fluorene-9-carboxylic acid-(4-bromo-anilide) 
• 872267-20-4 9-(hydroxy-di-m-tolyl-methyl)-fluorenol-⁽⁹⁾ 
• 858799-33-4 9-[hydroxy-bis-(4-methoxy-phenyl)-methyl]-fluorenol-⁽⁹⁾ 
• 109746-94-3 9-hydroxy-fluorene-9-carboxylic acid anilide 

Relevant academic research and scientific papers

Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: Identification of (3R)-3-{[hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2. 2.2]octane bromide (aclidinium bromide)

The objective of this work was to discover a novel, long-acting muscarinicM3 antagonist for the inhaled treatment of chronic obstructive pulmonary disease (COPD), with a potentially improved risk-benefit profile compared with current antimuscarinic agents. A series of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters were synthesized and evaluated. On the basis of its overall profile, (3R)-3-{[hydroxy(di-2-thienyl) acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (aclidiniumbromide) emerged as a candidate for once-daily maintenance treatment of COPD. This compound is a potent muscarinic antagonist, with long duration of action in vivo, and was found to have a rapid hydrolysis in human plasma, minimizing the potential to induce class-related systemic side effects. Aclidinium bromide is currently in phase III development for maintenance treatment of patients with COPD.

MEDICAMENTS FOR INHALATION COMPRISING ANTICHOLINERGICS AND A BETAMIMETIC

The present invention relates to novel pharmaceutical compositions comprising one or more, preferably one anticholinergic 1 and a betamimetic of formula 2 processes for preparing them and their use in the treatment of respiratory complaints.

Medicaments for inhalation comprising an anticholinergic and a betamimetic

A pharmaceutical composition comprising an anticholinergic and a betamimetic of formula 2 optionally together with a pharmaceutically acceptable excipient, the anticholinergic and the betamimetic optionally in the form of their enantiomers, mixtures of their enantiomers, their racemates, their solvates, or their hydrates, processes for preparing them, and their use in the treatment of asthma, COPD, or other inflammatory or obstructive respiratory complaints.

NEW PYRROLIDINIUM DERIVATIVES

New pyrrolidinium derivatives having the chemical structure of general formula (I) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as antagonists of M3 muscarinic receptors.

Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments

Flourenecarboxylic acid esters of general formula 1 wherein X? and the groups A, R, R1, R2, R3, R3′, R4, and R4′ have the meanings given in the claims and in the specification, processes for the manufacture thereof and the use thereof as medicaments.

Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions

A compound of formula 1 wherein: X? is an anion with a single negative charge; A and B, which are identical or different, are each —O—, —S—, —NH—, —CH2—, —CH═CH—, or —N(C1-C4-alkyl)-; R is hydrogen, hydroxy, —C1-C4-alkyl, —C1-C4-alkyloxy, —C1-C4-alkylene-halogen, —O—C1-C4-alkylene-halogen, —C1-C4-alkylene-OH, —CF3, —CHF2, —C1-C4-alkylene-C1-C4-alkyloxy, —O—COC1-C4-alkyl, —O—COC1-C4-alkylene-halogen, —C1-C4-alkylene-C3-C6-cycloalkyl, —O—COCF3, or halogen; R1 and R2, which are identical or different, are each —C1-C5-alkyl, which is optionally substituted by —C3-C6-cycloalkyl, hydroxy, or halogen, or R1 and R2 together are a —C3-C5-alkylene bridge; R3, R4, R3′, and R4′, which are identical or different, are each hydrogen, C1-C4-alkyl, C1-C4-alkyloxy, hydroxy, —CF3, —CHF2, —CN, —NO2, or halogen; Rx and Rx′, which are identical or different, are each hydrogen, C1-C4-alkyl, C1-C4-alkyloxy, hydroxy, —CF3, —CHF2, —CN, —NO2, or halogen, or Rx and Rx′ together are a single bond or a bridging group selected from —O—, —S—, —NH—, —CH2—, —CH2—CH2—, —N(C1-C4-alkyl)-, —CH(C1-C4-alkyl)-, and —C(C1-C4-alkyl)2-, or a pharmacologically acceptable acid addition salt thereof, processes for preparing, them and their use in pharmaceutical compositions.

BENZAMIDINE DERIVATIVES SUBSTITUTED BY CYCLIC AMINO ACID AND CYCLIC HYDROXY ACID DERIVATIVES AND THEIR USE AS ANTI-COAGULANTS

This invention is directed to benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives which are useful as anti-coagulants. This invention is also directed to pharmaceutical compositions containing the compounds of the invention, and methods of using the compounds to treat disease-states characterized by thrombotic activity.

Formation and Rearrangement of a 2,2-Dimethoxyoxirane from Dimethoxycarbene and Fluorenone

Thermolysis of 2,2-dimethoxy-5,5-dimethyl-Δ3-l,3,4-oxadiazoline (1) at 110 °C in the presence of 9-fluorenone (3) yielded 9-(dimethoxymethylene)fluorene oxide (4) and methyl 9-methoxyfluorene-9-carboxylate (5), which are the result of the addition of dimethoxycarbene (2) to the carbonyl group of 9-fluorenone. While the epoxide 4 is most likely generated from direct [2 + 1] cycloaddition, the ester 5 is the result of subsequent rearrangement of the oxirane. Thermolysis of the trideuteriomethoxy oxadiazoline 1-d3 in the presence of fluorenone showed that 5 is not formed by an intermolecular process because evidence for crossover of the label in the product 5 was not found. The rearrangement of 4 to 5 does not proceed by ring opening and intramolecular methyl transfer either but, instead, by ring opening and intramolecular methoxy transfer. Thus, as predicted by the Baldwin rules, the strained intramolecular 5-endo-tet methyl transfer is avoided in favor of another process.

Synthetic Routes to Indenopyridine Analogues of Morphactins

Investigation of a number of synthetic routes to aza analogues of Morphactins led to the synthesis of (RS)-methyl 5H-5-hydroxyindenopyridine-5-carboxylate (6e) and the corresponding carboamide, 6f.

Spiro-tricyclicaromatic succinimide derivatives

Disclosed are substituted or unsubstituted planar tricyclic fluorene or nuclear analogs thereof, spiro-coupled to a five-membered ring containing a secondary amide, and the pharmaceutically acceptable salts thereof. These compounds are useful, inter alia, in the treatment of diabetes. Also disclosed are processes for the preparation of such compounds; pharmaceutical compositions comprising such compounds; and methods of treatment comprising administering such compounds and compositions when indicated for, inter alia, long term, prophylactic treatment of the diabetes syndrome.